Loading…

Energetic description of cilengitide bound to integrin

The importance of integrins in several cell types that affect tumour progression has made them an appealing target for cancer therapy. In particular, the integrin α V β 3 plays an important role in angiogenesis and tumor cell metastasis, besides being evaluated as a target for new therapeutic approa...

Full description

Saved in:
Bibliographic Details
Published in:New journal of chemistry 2017, Vol.41 (19), p.11405-11412
Main Authors: Neto, José X. Lima, Bezerra, Katyanna S., Manso, Dalila N., Mota, Kyvia B., Oliveira, Jonas I. N., Albuquerque, Eudenilson L., Caetano, Ewerton W. S., Freire, Valder N., Fulco, Umberto L.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The importance of integrins in several cell types that affect tumour progression has made them an appealing target for cancer therapy. In particular, the integrin α V β 3 plays an important role in angiogenesis and tumor cell metastasis, besides being evaluated as a target for new therapeutic approaches. By employing quantum chemistry methods based on Density Functional Theory (DFT) within the Molecular Fractionation with Conjugate Caps (MFCC) approach, we investigated the binding energy features of cilengitide interacting with the integrin α V β 3 using a CPCM (Conductor-like Polarizable Continuum Model) scheme to represent the electrostatic environment through a dielectric constant. We have taken into account all ligand–residue interactions within a radius of 10 Å from the ligand, showing the most important regions of the ligand and the residues affecting the binding mechanism. Our computational results give a better understanding of the cilengitide–integrin binding mechanisms, while also being an efficient alternative towards the development of RGD (R, arginine; G, glycine; D, aspartic acid)-based drugs, prodrugs, nanoparticles and carriers, leading to new bio-engineering devices for cancer therapy.
ISSN:1144-0546
1369-9261
DOI:10.1039/C7NJ02166F